Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial.

Del Campo JM, Matulonis UA, Malander S, Provencher D, Mahner S, Follana P, Waters J, Berek JS, Woie K, Oza AM, Canzler U, Gil-Martin M, Lesoin A, Monk BJ, Lund B, Gilbert L, Wenham RM, Benigno B, Arora S, Hazard SJ, Mirza MR.

J Clin Oncol. 2019 Jun 7:JCO1802238. doi: 10.1200/JCO.18.02238. [Epub ahead of print]

PMID:
31173551
2.

Illuminating the Numbers: Integrating Mathematical Models to Optimize Photomedicine Dosimetry and Combination Therapies.

Spring BQ, Lang RT, Kercher EM, Rizvi I, Wenham RM, Conejo-Garcia JR, Hasan T, Gatenby RA, Enderling H.

Front Phys. 2019 Apr;7. pii: 46. doi: 10.3389/fphy.2019.00046. Epub 2019 Apr 2.

3.

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial.

Vergote I, Scambia G, O'Malley DM, Van Calster B, Park SY, Del Campo JM, Meier W, Bamias A, Colombo N, Wenham RM, Covens A, Marth C, Raza Mirza M, Kroep JR, Ma H, Pickett CA, Monk BJ; TRINOVA-3/ENGOT-ov2/GOG-3001 investigators.

Lancet Oncol. 2019 Jun;20(6):862-876. doi: 10.1016/S1470-2045(19)30178-0. Epub 2019 May 7.

PMID:
31076365
4.

Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial.

Fabbro M, Moore KN, Dørum A, Tinker AV, Mahner S, Bover I, Banerjee S, Tognon G, Goffin F, Shapira-Frommer R, Wenham RM, Hellman K, Provencher D, Harter P, Vázquez IP, Follana P, Pineda MJ, Mirza MR, Hazard SJ, Matulonis UA.

Gynecol Oncol. 2019 Mar;152(3):560-567. doi: 10.1016/j.ygyno.2018.12.009. Epub 2019 Jan 9.

5.

Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma.

Rose PG, Java JJ, Salani R, Geller MA, Secord AA, Tewari KS, Bender DP, Mutch DG, Friedlander ML, Van Le L, Method MW, Hamilton CA, Lee RB, Wenham RM, Guntupalli SR, Markman M, Muggia FM, Armstrong DK, Bookman MA, Burger RA, Copeland LJ.

Obstet Gynecol. 2019 Feb;133(2):245-254. doi: 10.1097/AOG.0000000000003086. Erratum in: Obstet Gynecol. 2019 Apr;133(4):830.

PMID:
30633128
6.

The role of menopausal hormone therapy in women with or at risk of ovarian and breast cancers: Misconceptions and current directions.

Temkin SM, Mallen A, Bellavance E, Rubinsak L, Wenham RM.

Cancer. 2019 Feb 15;125(4):499-514. doi: 10.1002/cncr.31911. Epub 2018 Dec 20. Review.

PMID:
30570740
7.

Corrigendum to "Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study" [Gynecol. Oncol. 151 (2018) 18-23].

Olawaiye AB, Java JJ, Krivak TC, Friedlander M, Mutch DG, Glaser G, Geller M, O'Malley DM, Wenham RM, Lee RB, Bodurka DC, Herzog TJ, Bookman MA.

Gynecol Oncol. 2019 Jan;152(1):220. doi: 10.1016/j.ygyno.2018.10.022. Epub 2018 Oct 23. No abstract available.

8.

Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study.

Olawaiye AB, Java JJ, Krivak TC, Friedlander M, Mutch DG, Glaser G, Geller M, O'Malley DM, Wenham RM, Lee RB, Bodurka DC, Herzog TJ, Bookman MA.

Gynecol Oncol. 2018 Oct;151(1):18-23. doi: 10.1016/j.ygyno.2018.07.021. Epub 2018 Aug 19. Erratum in: Gynecol Oncol. 2018 Oct 22;:.

PMID:
30135020
9.

Surgical prevention strategies in ovarian cancer.

Mallen A, Soong TR, Townsend MK, Wenham RM, Crum CP, Tworoger SS.

Gynecol Oncol. 2018 Oct;151(1):166-175. doi: 10.1016/j.ygyno.2018.08.005. Epub 2018 Aug 4. Review.

PMID:
30087058
10.

Quality of life after pelvic exenteration for gynecologic cancer: Findings from a qualitative study.

Nelson AM, Albizu-Jacob A, Fenech AL, Chon HS, Wenham RM, Donovan KA.

Psychooncology. 2018 Oct;27(10):2357-2362. doi: 10.1002/pon.4832. Epub 2018 Jul 18.

PMID:
29956389
11.

Adherence to practice guidelines is associated with reduced referral times for patients with ovarian cancer.

Boac BM, Xiong Y, Apte SM, Wenham RM, Shahzad MM, Munroe DG, Lancaster JM, Chon HS.

Am J Obstet Gynecol. 2018 Apr;218(4):436.e1-436.e7. doi: 10.1016/j.ajog.2018.01.015. Epub 2018 Jan 17.

PMID:
29353030
12.

New therapies for advanced, recurrent, and metastatic endometrial cancers.

Makker V, Green AK, Wenham RM, Mutch D, Davidson B, Miller DS.

Gynecol Oncol Res Pract. 2017 Dec 2;4:19. doi: 10.1186/s40661-017-0056-7. eCollection 2017. Review.

13.

Gene Expression Signature-Based Prediction of Lymph Node Metastasis in Patients With Endometrioid Endometrial Cancer.

Kang S, Thompson Z, McClung EC, Abdallah R, Lee JK, Gonzalez-Bosquet J, Wenham RM, Chon HS.

Int J Gynecol Cancer. 2018 Feb;28(2):260-266. doi: 10.1097/IGC.0000000000001152.

14.

Surgical outcomes among elderly women with endometrial cancer treated by laparoscopic hysterectomy: a NRG/Gynecologic Oncology Group study.

Bishop EA, Java JJ, Moore KN, Spirtos NM, Pearl ML, Zivanovic O, Kushner DM, Backes F, Hamilton CA, Geller MA, Hurteau J, Mathews C, Wenham RM, Ramirez PT, Zweizig S, Walker JL.

Am J Obstet Gynecol. 2018 Jan;218(1):109.e1-109.e11. doi: 10.1016/j.ajog.2017.09.026. Epub 2017 Oct 14.

15.

Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.

Moore KN, Tritchler D, Kaufman KM, Lankes H, Quinn MCJ; Ovarian Cancer Association Consortium, Van Le L, Berchuck A, Backes FJ, Tewari KS, Lee RB, Kesterson JP, Wenham RM, Armstrong DK, Krivak TC, Bookman MA, Birrer MJ.

Gynecol Oncol. 2017 Nov;147(2):396-401. doi: 10.1016/j.ygyno.2017.08.024. Epub 2017 Sep 19.

16.

Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers.

Chon HS, Kang S, Lee JK, Apte SM, Shahzad MM, Williams-Elson I, Wenham RM.

BMC Cancer. 2017 Jun 8;17(1):407. doi: 10.1186/s12885-017-3394-2.

17.

Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study.

Mai PL, Piedmonte M, Han PK, Moser RP, Walker JL, Rodriguez G, Boggess J, Rutherford TJ, Zivanovic O, Cohn DE, Thigpen JT, Wenham RM, Friedlander ML, Hamilton CA, Bakkum-Gamez J, Olawaiye AB, Hensley ML, Greene MH, Huang HQ, Wenzel L.

Gynecol Oncol. 2017 Apr;145(1):122-129. doi: 10.1016/j.ygyno.2017.02.008. Epub 2017 Feb 10.

18.

ERBB4 Expression in Ovarian Serous Carcinoma Resistant to Platinum-Based Therapy.

Saglam O, Xiong Y, Marchion DC, Strosberg C, Wenham RM, Johnson JJ, Saeed-Vafa D, Cubitt C, Hakam A, Magliocco AM.

Cancer Control. 2017 Jan;24(1):89-95.

PMID:
28178720
19.

ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer.

Marth C, Vergote I, Scambia G, Oberaigner W, Clamp A, Berger R, Kurzeder C, Colombo N, Vuylsteke P, Lorusso D, Hall M, Renard V, Pignata S, Kristeleit R, Altintas S, Rustin G, Wenham RM, Mirza MR, Fong PC, Oza A, Monk BJ, Ma H, Vogl FD, Bach BA.

Eur J Cancer. 2017 Jan;70:111-121. doi: 10.1016/j.ejca.2016.09.004. Epub 2016 Dec 1.

PMID:
27914241
20.

What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study.

Rungruang BJ, Miller A, Krivak TC, Horowitz NS, Rodriguez N, Hamilton CA, Backes FJ, Carson LF, Friedlander M, Mutch DG, Goodheart MJ, Tewari KS, Wenham RM, Bookman MA, Maxwell GL, Richard SD.

Cancer. 2017 May 15;123(6):985-993. doi: 10.1002/cncr.30414. Epub 2016 Nov 16.

21.

MicroRNA MiR-214 regulates ovarian cancer cell stemness by targeting p53/Nanog.

Xu CX, Xu M, Tan L, Yang H, Permuth-Wey J, Kruk PA, Wenham RM, Nicosia SV, Lancaster JM, Sellers TA, Cheng JQ.

J Biol Chem. 2016 Oct 21;291(43):22851. No abstract available.

22.

Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives.

McClung EC, Wenham RM.

Int J Womens Health. 2016 Mar 15;8:59-75. doi: 10.2147/IJWH.S78101. eCollection 2016. Review.

23.

Sensitivity of ovarian cancer cells to acetaminophen reveals biological pathways that affect patient survival.

Bush SH, Tollin S, Marchion DC, Xiong Y, Abbasi F, Ramirez IJ, Zgheib NB, Boac B, Judson PL, Chon HS, Wenham RM, Apte SM, Cubitt CL, Berglund AE, Havrilesky LJ, Lancaster JM.

Mol Clin Oncol. 2016 Mar;4(3):399-404. Epub 2016 Jan 7.

24.

Molecular determinants for lymph node metastasis in clinically early-stage endometrial cancer.

Bou Zgheib N, Marchion DC, Bush SH, Judson PL, Wenham RM, Apte SM, Lancaster JM, Gonzalez-Bosquet J.

Oncol Lett. 2016 Jan;11(1):323-329. Epub 2015 Nov 6.

25.

Therapeutic Dilemma: Prognostic Factors and Outcome for Neuroendocrine Tumors of the Cervix.

Abdallah R, Bush SH, Chon HS, Apte SM, Wenham RM, Shahzad MM.

Int J Gynecol Cancer. 2016 Mar;26(3):553-60. doi: 10.1097/IGC.0000000000000631.

PMID:
26825841
26.

Micro-RNAs associated with the evolution of ovarian cancer cisplatin resistance.

Boac BM, Xiong Y, Marchion DC, Abbasi F, Bush SH, Ramirez IJ, Khulpateea BR, Clair McClung E, Berry AL, Bou Zgheib N, Chon HS, Shahzad MM, Judson PL, Wenham RM, Apte SM, Berglund AE, Magliocco AM, Lancaster JM.

Gynecol Oncol. 2016 Feb;140(2):259-63. doi: 10.1016/j.ygyno.2015.12.026. Epub 2015 Dec 28.

27.

Right Place, Right Time: Preferences of Women with Ovarian Cancer for Delivery of CAM Education.

Ebbert JA, Donovan KA, Lengacher CA, Fabri D, Reich R, Daley E, Thompson EL, Wenham RM.

Medicines (Basel). 2015 Aug 31;2(3):236-250. doi: 10.3390/medicines2030236.

28.

Prediction of Optimal Cytoreductive Surgery of Serous Ovarian Cancer With Gene Expression Data.

Abdallah R, Chon HS, Bou Zgheib N, Marchion DC, Wenham RM, Lancaster JM, Gonzalez-Bosquet J.

Int J Gynecol Cancer. 2015 Jul;25(6):1000-9. doi: 10.1097/IGC.0000000000000449.

PMID:
26098088
29.

BAD-mediated apoptotic pathway is associated with human cancer development.

Stickles XB, Marchion DC, Bicaku E, Al Sawah E, Abbasi F, Xiong Y, Bou Zgheib N, Boac BM, Orr BC, Judson PL, Berry A, Hakam A, Wenham RM, Apte SM, Berglund AE, Lancaster JM.

Int J Mol Med. 2015 Apr;35(4):1081-7. doi: 10.3892/ijmm.2015.2091. Epub 2015 Feb 5.

30.

A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours.

Brana I, Berger R, Golan T, Haluska P, Edenfield J, Fiorica J, Stephenson J, Martin LP, Westin S, Hanjani P, Jones MB, Almhanna K, Wenham RM, Sullivan DM, Dalton WS, Gunchenko A, Cheng JD, Siu LL, Gray JE.

Br J Cancer. 2014 Nov 11;111(10):1932-44. doi: 10.1038/bjc.2014.497. Epub 2014 Oct 7.

31.

The Chinese herb polyphyllin D sensitizes ovarian cancer cells to cisplatin-induced growth arrest.

Al Sawah E, Marchion DC, Xiong Y, Ramirez IJ, Abbasi F, Boac BM, Bush SH, Bou Zgheib N, McClung EC, Khulpateea BR, Berry A, Hakam A, Wenham RM, Lancaster JM, Judson PL.

J Cancer Res Clin Oncol. 2015 Feb;141(2):237-42. doi: 10.1007/s00432-014-1797-x. Epub 2014 Aug 28.

PMID:
25164128
32.

A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer.

Vergote I, Schilder RJ, Pippitt CH Jr, Wong S, Gordon AN, Scudder S, Kridelka F, Dirix L, Leach JW, Ananda S, Nanayakkara N, Melara R, Bass MB, Litten J, Adewoye H, Wenham RM.

Gynecol Oncol. 2014 Oct;135(1):25-33. doi: 10.1016/j.ygyno.2014.07.003. Epub 2014 Jul 11.

33.

Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer.

Schwandt A, von Gruenigen VE, Wenham RM, Frasure H, Eaton S, Fusco N, Fu P, Wright JJ, Dowlati A, Waggoner S.

Invest New Drugs. 2014 Aug;32(4):729-38. doi: 10.1007/s10637-014-0078-5. Epub 2014 Mar 12.

PMID:
24619298
34.

A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube.

Herzog TJ, Monk BJ, Rose PG, Braly P, Hines JF, Bell MC, Wenham RM, Secord AA, Roman LD, Einstein MH, Drake RD, Childs BH.

Gynecol Oncol. 2014 Mar;132(3):517-25. doi: 10.1016/j.ygyno.2014.01.035. Epub 2014 Jan 27.

35.

Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel.

Chen N, Chon HS, Xiong Y, Marchion DC, Judson PL, Hakam A, Gonzalez-Bosquet J, Permuth-Wey J, Wenham RM, Apte SM, Cheng JQ, Sellers TA, Lancaster JM.

Oncol Rep. 2014 Jan;31(1):376-83. doi: 10.3892/or.2013.2847. Epub 2013 Nov 13.

36.

Evidence of a chemopreventive effect of progestin unrelated to ovulation on reproductive tract cancers in the egg-laying hen.

Rodriguez GC, Barnes HJ, Anderson KE, Whitaker RS, Berchuck A, Petitte JN, Lancaster JM, Wenham RM, Turbov JM, Day R, Maxwell GL, Carver DK.

Cancer Prev Res (Phila). 2013 Dec;6(12):1283-92. doi: 10.1158/1940-6207.CAPR-12-0426. Epub 2013 Oct 17.

37.

Gene expression data reveal common pathways that characterize the unifocal nature of ovarian cancer.

Marchion DC, Xiong Y, Chon HS, Al Sawah E, Bou Zgheib N, Ramirez IJ, Abbasi F, Stickles XB, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Berglund AE, Lancaster JM.

Am J Obstet Gynecol. 2013 Dec;209(6):576.e1-576.e16. doi: 10.1016/j.ajog.2013.08.004. Epub 2013 Aug 9.

38.

Perifosine, an AKT inhibitor, modulates ovarian cancer cell line sensitivity to cisplatin-induced growth arrest.

Al Sawah E, Chen X, Marchion DC, Xiong Y, Ramirez IJ, Abbasi F, Bou Zgheib N, Chon HS, Wenham RM, Apte SM, Judson PL, Lancaster JM.

Gynecol Oncol. 2013 Oct;131(1):207-12. doi: 10.1016/j.ygyno.2013.07.088. Epub 2013 Jul 20.

PMID:
23877012
39.

The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.

Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, Hylands L, Riisnaes R, Forster M, Omlin A, Kreischer N, Thway K, Gevensleben H, Sun L, Loughney J, Chatterjee M, Toniatti C, Carpenter CL, Iannone R, Kaye SB, de Bono JS, Wenham RM.

Lancet Oncol. 2013 Aug;14(9):882-92. doi: 10.1016/S1470-2045(13)70240-7. Epub 2013 Jun 28.

PMID:
23810788
40.

A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy.

Wenham RM, Lapolla J, Lin HY, Apte SM, Lancaster JM, Judson PL, Gonzalez-Bosquet J, Herschberger A, Havrilesky LJ, Secord AA.

Gynecol Oncol. 2013 Jul;130(1):19-24. doi: 10.1016/j.ygyno.2013.04.049. Epub 2013 Apr 25.

PMID:
23623830
41.

Factors associated with improved toxicity and tolerability of intraperitoneal chemotherapy in advanced-stage epithelial ovarian cancers.

Teefey P, Bou Zgheib N, Apte SM, Gonzalez-Bosquet J, Judson PL, Roberts WS, Lancaster JM, Wenham RM.

Am J Obstet Gynecol. 2013 Jun;208(6):501.e1-7. doi: 10.1016/j.ajog.2013.03.012. Epub 2013 Mar 15.

PMID:
23507546
42.

A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth.

Marchion DC, Bicaku E, Xiong Y, Bou Zgheib N, Al Sawah E, Stickles XB, Judson PL, Lopez AS, Cubitt CL, Gonzalez-Bosquet J, Wenham RM, Apte SM, Berglund A, Lancaster JM.

Oncol Rep. 2013 May;29(5):2011-8. doi: 10.3892/or.2013.2329. Epub 2013 Mar 5.

43.

Lagged relationships among sleep disturbance, fatigue, and depressed mood during chemotherapy.

Jim HS, Jacobsen PB, Phillips KM, Wenham RM, Roberts W, Small BJ.

Health Psychol. 2013 Jul;32(7):768-74. doi: 10.1037/a0031322. Epub 2013 Feb 25.

44.

MicroRNA miR-214 regulates ovarian cancer cell stemness by targeting p53/Nanog.

Xu CX, Xu M, Tan L, Yang H, Permuth-Wey J, Kruk PA, Wenham RM, Nicosia SV, Lancaster JM, Sellers TA, Cheng JQ.

J Biol Chem. 2012 Oct 12;287(42):34970-8. doi: 10.1074/jbc.M112.374611. Epub 2012 Aug 27. Retraction in: J Biol Chem. 2016 Oct 21;291(43):22851.

45.

The creation of an integrated health-information platform: building the framework to support personalized medicine.

Wenham RM, Sullivan DM, Hulse M, Jacobsen PB, Dalton WS.

Per Med. 2012 Aug;9(6):621-632. doi: 10.2217/pme.12.76.

PMID:
29768801
46.

A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer.

Secord AA, Teoh DK, Barry WT, Yu M, Broadwater G, Havrilesky LJ, Lee PS, Berchuck A, Lancaster J, Wenham RM.

Clin Cancer Res. 2012 Oct 1;18(19):5489-98. doi: 10.1158/1078-0432.CCR-12-0507. Epub 2012 Jul 26.

47.

Characterizing the efficacy of fermented wheat germ extract against ovarian cancer and defining the genomic basis of its activity.

Judson PL, Al Sawah E, Marchion DC, Xiong Y, Bicaku E, Bou Zgheib N, Chon HS, Stickles XB, Hakam A, Wenham RM, Apte SM, Gonzalez-Bosquet J, Chen DT, Lancaster JM.

Int J Gynecol Cancer. 2012 Jul;22(6):960-7. doi: 10.1097/IGC.0b013e318258509d.

48.

In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival.

Bicaku E, Xiong Y, Marchion DC, Chon HS, Stickles XB, Chen N, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Fulp W, Cubitt CL, Chen DT, Lancaster JM.

Br J Cancer. 2012 Jun 5;106(12):1967-75. doi: 10.1038/bjc.2012.207. Epub 2012 May 17.

49.

The O-glycan pathway is associated with in vitro sensitivity to gemcitabine and overall survival from ovarian cancer.

Bou Zgheib N, Xiong Y, Marchion DC, Bicaku E, Chon HS, Stickles XB, Sawah EA, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Cubitt CL, Chen DT, Lancaster JM.

Int J Oncol. 2012 Jul;41(1):179-88. doi: 10.3892/ijo.2012.1451. Epub 2012 Apr 26.

50.

BCL2 antagonist of cell death kinases, phosphatases, and ovarian cancer sensitivity to cisplatin.

Bansal N, Marchion DC, Bicaku E, Xiong Y, Chen N, Stickles XB, Sawah EA, Wenham RM, Apte SM, Gonzalez-Bosquet J, Judson PL, Hakam A, Lancaster JM.

J Gynecol Oncol. 2012 Jan;23(1):35-42. doi: 10.3802/jgo.2012.23.1.35. Epub 2012 Jan 9.

Supplemental Content

Loading ...
Support Center